Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) infection
Remdesivir (RDV) is an experimental drug being developed by Gilead Sciences. In experiments it has shown activity against SARS-2-CoV and multiple other similar types of viruses.
Participants will receive Remdesivir (RDV) intravenously for 10 days. Participants will also complete questionnaires, blood and urine tests, vital measurements, and physical exams. Researchers will review participant medical records and contact participants via phone on Days 15 and 28 to follow up.
- IRB Number: 2004458049
- Research Study Identifier: 2004458049